ClinicalTrials.gg
RecruitingNCT07784907Updated Aug 25, 2026

Efficacy of Platelet-Rich Plasma Combined With Hyaluronic Acid in Knee Osteoarthritis

An interventional study of Hyaluronic Acid (HA) and Platelet rich plasma (PRP) and Hyaluronic Acid (HA) in Knee Osteoarthritis, Knee Osteoarthritis (Knee OA) and Knee Osteoarthritis (OA), sponsored by Implai Sp z o.o. Recruiting at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-25.

Sponsored by Implai Sp z o.o · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 77 studies in Osteoarthritis, Knee with a site in Poland — 12 open to participants now, 13 under way, 2 of them phase 3. Osteoarthritis, Knee · Poland.

Planned enrollment
38th of 71
100 · median 120
Started
2026
with 9 others
No phase
27 of 77
9 open now
Primary completion
2028-07
later than 8 of 12 live
Registered
74th of 77
by date
Lead sponsor
2 of 77
Implai Sp z o.o

Among the 77 studies in Osteoarthritis, Knee with a site in Poland, this one is the 38th largest by planned enrollment of the 71 interventional ones that give a count, is one of 10 that started in 2026, is one of 27 with no phase, reaches primary completion later than 8 of the 12 other live ones, and was the 74th registered.

Osteoarthritis, Knee

3,295 studies on the registry are indexed under Osteoarthritis, Knee; 624 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

12 of the 77 studies in Osteoarthritis, Knee with a site in Poland are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 383 Osteoarthritis, Knee studies recruiting now, 177 (46%) set no upper age limit and 113 (30%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Osteoarthritis, Knee with a site in Poland, or all of them as a file.
02

Study summary

This prospective, randomized, open-label, single-centre post-market clinical follow-up (PMCF) study evaluates the clinical performance and safety of a single intra-articular injection of hyaluronic acid (HA) combined with autologous platelet-rich plasma (PRP) compared with a single intra-articular injection of HA alone in adults with symptomatic knee osteoarthritis (Kellgren-Lawrence grade II or III).

Knee osteoarthritis is a chronic degenerative joint disease associated with pain, functional limitations, and reduced quality of life. Hyaluronic acid is widely used as viscosupplementation therapy, while platelet-rich plasma provides autologous growth factors that may contribute to the modulation of inflammatory processes and tissue healing. The combination of HA and PRP may provide complementary effects and may offer additional clinical benefit compared with HA alone.

A total of 50 participants will be randomized in a 1:1 ratio to receive either a single intra-articular injection of 3.8 mL HA combined with 1 mL autologous PRP or a single intra-articular injection of 4.8 mL HA. Participants will be followed for 18 months.

The primary endpoint is the between-group difference in the change in knee pain, measured using the Numeric Rating Scale (NRS), from baseline to Month 6. Secondary outcomes include changes in pain intensity, the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), the Knee Injury and Osteoarthritis Outcome Score (KOOS), quality-of-life measures, and safety assessments throughout the follow-up period.

Both medical devices are CE-marked and are used for their intended purpose. The study is conducted as a PMCF investigation in accordance with Regulation (EU) 2017/745 (MDR).

03

Conditions studied

  • Knee Osteoarthritis
  • Knee Osteoarthritis (Knee OA)
  • Knee Osteoarthritis (OA)
  • Osteoarthritis (OA) of the Knee

Keywords

  • hyaluronic acid
  • PRP
  • HA
  • intra-articular injection
  • Single intra-articular injection
  • knee osteoarthritis
  • viscosupplementation
  • Hyaluronic acid and platelet-rich plasma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Knee osteoarthritis meeting American College of Rheumatology (ACR) criteria
  • Kellgren-Lawrence radiographic grade II or III
  • Pain intensity in the study knee NRS >= 4 and in the contralateral knee NRS \<= 2
  • Written

Exclusion criteria

Exclusion Criteria:

  • >= 40 kg/m2
  • Surgery of the same or contralateral knee within the previous year
  • Intra-articular injection into the study joint within 3 months, or hyaluronic acid, -rich plasma or other intra-articular injection therapy within 6 months before enrolment
  • Systemic corticosteroid use within 2 weeks
  • Systemic inflammatory or disease with joint involvement (rheumatoid arthritis, spondyloarthropathy, systemic lupus erythematosus, etc.)
  • Oral corticosteroid treatment
  • Deep vein thrombosis
  • Pregnancy or breastfeeding
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Hyaluronic acid with autologous plateletrich plasma

    Single intra-articular knee injection of 3.8 mL hyaluronic acid combined with 1 mL autologous platelet-rich plasma (PRP), prepared from 13.5 mL of the participant's venous blood using the PRP separation device (total injection volume: 4.8 mL).

    Device: Hyaluronic Acid (HA) and Platelet rich plasma (PRP)

  • Active comparator
    Hyaluronic acid

    Single intra-articular knee injection of 4.8 mL hyaluronic acid gel containing sodium hyaluronate (25 mg/mL; total dose: 120 mg).

    Device: Hyaluronic Acid (HA)

Interventions

  • DeviceHyaluronic Acid (HA) and Platelet rich plasma (PRP)

    Procedure kit enabling preparation of autologous platelet-rich plasma (PRP) from the participant's venous blood and intra-articular administration combined with sodium hyaluronate. The procedure includes preparation of PRP using a separation device and injection of a total volume of 4.8 mL consisting of 3.8 mL of 2.5% sodium hyaluronate and 1 mL of autologous PRP.

  • DeviceHyaluronic Acid (HA)

    Pre-filled syringe containing 4.8 mL of sterile, nonpyrogenic hyaluronic acid gel for intra-articular injection. The product contains sodium hyaluronate at a concentration of 25 mg/mL (total dose: 120 mg), produced by bacterial fermentation and of non-animal origin.

06

What researchers measure

Primary outcomes

  1. Change in knee pain intensity on the Numeric Rating Scale (NRS)

    The Numeric Rating Scale (NRS) for pain is an 11-point single-item scale on which the participant rates knee pain intensity over the past week from 0 (no pain) to 10 (worst imaginable pain). The outcome is the between-group difference in change from baseline; a greater decrease indicates greater improvement.

    Time frame: Baseline to 6 months

Secondary outcomes

  1. Change in knee pain intensity as measured by the Numeric Rating Scale (NRS) at additional time points

    The Numeric Rating Scale (NRS) for pain ranges from 0 (no pain) to 10 (worst imaginable pain). Change from baseline is reported; a decrease indicates improvement.

    Time frame: Baseline, 1, 3, 12 and 18 months

  2. Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores

    The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) consists of three subscales: Pain, Stiffness, and Physical Function. The total WOMAC score ranges from 0 to 96, with higher scores indicating worse pain, stiffness, and physical function. The Pain subscale ranges from 0 to 20, the Stiffness subscale from 0 to 8, and the Physical Function subscale from 0 to 68. Change from baseline will be assessed for the total WOMAC score and each subscale score. A decrease in score indicates improvement.

    Time frame: Baseline, 1, 3, 6, 12 and 18 months

  3. Change in Knee Injury and Osteoarthritis Outcome Score (KOOS) subscale scores

    The Knee Injury and Osteoarthritis Outcome Score (KOOS) consists of five subscales: Symptoms, Pain, Activities of Daily Living, Sport and Recreation, and Knee-related Quality of Life. Each subscale is normalised to a 0-100 scale, where 0 indicates extreme knee problems and 100 indicates no knee problems. Change from baseline will be assessed for each KOOS subscale; an increase in score indicates improvement.

    Time frame: Baseline to 18 months

  4. Number of participants with at least one treatment-emergent adverse event (AE)

    Number of participants experiencing at least one adverse event (AE) of any grade after the study injection, as recorded at every study visit.

    Time frame: Baseline to 18 months

  5. Number of treatment-emergent adverse events (AEs)

    Total count of adverse events (AEs) reported after the study injection, summarised by event type.

    Time frame: Baseline to 18 months]

  6. Number of participants discontinuing the study due to an adverse event (AE)

    Number of participants who did not complete the study because of an adverse event (AE).

    Time frame: Baseline to 18 months

07

Study locations

1 of 1 sites recruiting
  • Przychodnia Specjalistyczna Lancet
    Chełm, Lublin Voivodeship 22-100, Poland
    Recruiting
    • Jaromir Jarecki, DSc · Contactjaromirj@interia.pl · +48 82 575 05 75
    • Jaromir Jarecki, DSc · Principal investigator
    • Andrzej Kosior, MD · Sub investigator
    • Piotr Kosior, MD, PhD · Sub investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jul 2028, 24 months after the start.

Of 140 industry-sponsored interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 34. This study's planned 24 months is above that.

Counting every sponsor, half of 1,251 studies reached it within 18 months; a quarter within 8 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2026
First posted
Aug 25, 2026
StartActual
Jul 20, 2026
Primary completionEst.
Jul 2028
CompletionEst.
Jul 2028
Last update
Aug 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07784907
Lead sponsor
Implai Sp z o.o
Responsible party
Sponsor
First posted
Aug 25, 2026
Start date
Jul 20, 2026
Primary completion
Jul 2028 (estimated)
Completion
Jul 2028 (estimated)
Last update
Aug 25, 2026

Study contacts

Eliza Fiedorczuk
Contact
clinical@implai.com
+48 58 660 44 88
Jaromir Jarecki, DSc
principal investigator · Przychodnia Specjalistyczna Lancet

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion